Cheng Li

Prof. Dr. Cheng Li

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Phytomedicine
Verified
Journal Article
Closed access
YHYi Han
Yi Han
SGShujia Guo
Shujia Guo
YLYunpeng Li
Yunpeng Li
JLJiani Li
Jiani Li
LZLinfangzi Zhu
Linfangzi Zhu
ZLZuguo Liu
Zuguo Liu

30 April 2023 in Nano-Micro Letters
Verified
Journal Article
Open access
PDF file
YTYonghua Tang
Yonghua Tang
YHYi Han
Yi Han
JZJiachen Zhao
Jiachen Zhao
YLYufei Lv
Yufei Lv
CFChaoyu Fan
Chaoyu Fan
YLYouhui Lin
Youhui Lin
Metal–organic frameworks (MOFs) have attracted significant research interest in biomimetic catalysis. However, the modulation of the activity of MOFs by precisely tuning the coordination of metal nodes is still a significant challenge. Inspired by metalloenzymes with well-defined coordination structures, a series of MOFs containing halogen-coordinated copper nodes (Cu-X MOFs, X = Cl, Br, I) are employed to elucidate their structure–activity relationship. Intriguingly, experimental and theoretical results strongly support that precisely tuning the coordination of halogen atoms directly regulates the enzyme-like activities of Cu-X MOFs by influencing the spatial configuration and electronic structure of the Cu active center. The optimal Cu–Cl MOF exhibits excellent superoxide dismutase-like activity with a specific activity one order of magnitude higher than the reported Cu-based nanozymes. More importantly, by performing enzyme-mimicking catalysis, the Cu–Cl MOF nanozyme can significantly scavenge reactive oxygen species and alleviate oxidative stress, thus effectively relieving ocular chemical burns. Mechanistically, the antioxidant and antiapoptotic properties of Cu–Cl MOF are achieved by regulating the NRF2 and JNK or P38 MAPK pathways. Our work provides a novel way to refine MOF nanozymes by directly engineering the coordination microenvironment and, more significantly, demonstrating their potential therapeutic effect in ophthalmic disease.

15 January 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JGJingxun Guo
Jingxun Guo
ZLZhen Liu
Zhen Liu
PWPengjun Wang
Pengjun Wang
HWHeming Wu
Heming Wu
KFKai Fan
Kai Fan
CLCheng Li
Cheng Li
Background: Chronic kidney disease (CKD) is a significant global health issue, often linked to diabetes, hypertension, and glomerulonephritis. However, aggregated statistics can obscure heterogeneity across subtypes, age, gender, and regions. This study aimed to analyze global CKD trends from 1990 to 2021, focusing on age, gender, socio-demographic index (SDI), and regional variations.Methods: Data were extracted from the Global Burden of Disease (GBD) 2021 database, covering prevalence, incidence, mortality, and disability-adjusted life years (DALYs). These were presented as counts per 100,000 population and age-standardized rates, with uncertainty intervals (UIs) to highlight variability. Joinpoint regression was used to assess trends over the 30-year period.Results: In 2021, global CKD prevalence was 359 million, with 11.13 million new cases, 1.53 million deaths, and 44.45 million DALYs—up 92, 156, 176, and 114% since 1990. While prevalence slightly declined, incidence, mortality, and DALYs increased significantly. CKD burden varied by region and age, with notable gender disparities.Conclusion: The study highlights a dramatic rise in CKD burden linked to population growth and aging, emphasizing the need for targeted treatment and effective global healthcare policies.

28 July 2021 in Bioactive Materials
Verified
Journal Article
Open access
YHYi Han
Yi Han
LJLu Jiang
Lu Jiang
HSHuihui Shi
Huihui Shi
CXChenfang Xu
Chenfang Xu
LMLiu Minting
Liu Minting
CLCheng Li
Cheng Li
Dry eye is a common ocular disease that results in discomfort and impaired vision, impacting an individual's quality of life. A great number of drugs administered in eye drops to treat dry eye are poorly soluble in water and are rapidly eliminated from the ocular surface, which limits their therapeutic effects. Therefore, it is imperative to design a novel drug delivery system that not only improves the water solubility of the drug but also prolongs its retention time on the ocular surface. Herein, we develop a copolymer from mono-functional POSS, PEG, and PPG (MPOSS-PEG-PPG, MPEP) that exhibits temperature-sensitive sol-gel transition behavior. This thermo-responsive hydrogel improves the water solubility of FK506 and simultaneously provides a mucoadhesive, long-acting ocular delivery system. In addition, the FK506-loaded POSS hydrogel possesses good biocompatibility and significantly improves adhesion to the ocular surface. In comparison with other FK506 formulations and the PEG-PPG-FK506 (F127-FK506) hydrogel, this novel MPOSS-PEG-PPG-FK506 (MPEP-FK506) hydrogel is a more effective treatment of dry eye in the murine dry eye model. Therefore, delivery of FK506 in this POSS hydrogel has the potential to prolong drug retention time on the ocular surface, which will improve its therapeutic efficacy in the management of dry eye.

10 August 2021 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
ZLZhiguo Li
Zhiguo Li
MLMinting Liu
Minting Liu
LKLingjie Ke
Lingjie Ke
LWLi-Juan Wang
Li-Juan Wang
CWCaisheng Wu
Caisheng Wu
Yun-Long WuYun-Long Wu
Yun-Long Wu
The eye is a complex structure with a variety of anatomical barriers and clearance mechanisms, so the provision of safe and effective ophthalmic drug delivery technology is a major challenge.

1 August 2021 in Talanta
Verified
Journal Article
Closed access
YTYingzhou Tao
Yingzhou Tao
FLFang Luo
Fang Luo
YLYisheng Lin
Yisheng Lin
NDNuo Dong
Nuo Dong
CLCheng Li
Cheng Li
zhenyu Linzhenyu Lin
zhenyu Lin